<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6115">
  <stage>Registered</stage>
  <submitdate>15/08/2016</submitdate>
  <approvaldate>15/08/2016</approvaldate>
  <nctid>NCT02875366</nctid>
  <trial_identification>
    <studytitle>A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation</studytitle>
    <scientifictitle>A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-000066-34</secondaryid>
    <secondaryid>VX15-809-112</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LUM/IVA
Treatment: drugs - Placebo

Experimental: LUM/IVA - LUM 400 mg every 12 hours (q12h)/IVA 250 mg q12h

Experimental: Placebo - Placebo


Treatment: drugs: LUM/IVA


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage change from baseline in maximal oxygen consumption (VO2max) during cardiopulmonary exercise testing (CPET)</outcome>
      <timepoint>at Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in exercise duration during CPET</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in oxygen consumption (VO2) at anaerobic threshold (AT)</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in functional VO2 gain</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the pulmonary ventilation (VE) versus carbon dioxide production (VCO2) slope</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1)</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in body mass index (BMI)</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Cystic Fibrosis Questionnaire-Revised (CFQ R) respiratory domain score</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in overall Patient Health Questionnaire (PHQ-8) and Generalized Anxiety Disorder (GAD-7) scores</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in physical activity as determined by actigraphy</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in duration of sleep time during the night</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in sleep quality during the night</outcome>
      <timepoint>at Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs) - (for subjects under 18 years of age only).</outcome>
      <timepoint>Baseline to Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Homozygous for the F508del CFTR mutation

          -  Confirmed diagnosis of CF defined as a sweat chloride value =60 mmol/L by quantitative
             pilocarpine iontophoresis

          -  Stable CF disease as judged by the investigator.

          -  FEV1 at least 40% and not greater than 90% of predicted.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any comorbidity that might confound the results of the study, interfere
             with the use of CPET as an assessment, or pose an additional risk in administering
             study drug to the subject.

          -  Any previous exposure to LUM or IVA

          -  History of cardiac arrhythmia, ischemic heart disease, congestive heart failure, or
             other clinically significant cardiac condition, or medical condition requiring chronic
             use of a beta blocker, non-dihydropyridine calcium channel blocker, or other cardiac
             medication known to affect exercise tolerance.

          -  History of solid organ or hematological transplantation.

          -  For subjects under 18 years of age at Screening, except those who have had bilateral
             lens removal, selected findings on a screening ophthalmologic examination will be
             exclusionary

          -  Using or expected to require any concomitant medication that is prohibited in this
             study

          -  History of alcohol or drug abuse, as deemed by the investigator, in the past year,
             including but not limited to cannabis, cocaine, and opiates.

          -  Participation in an investigational drug study within 30 days before the Screening
             Visit.

          -  Pregnant or nursing females; males with a female partner who is pregnant or nursing.

          -  Colonization with organisms associated with a more rapid decline in pulmonary status</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Melbourne</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Camperdown</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Nedlands</hospital>
    <hospital> - New Lambton Heights</hospital>
    <hospital> - Randwick</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - Subiaco</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - New Lambton Heights</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Subiaco</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in
      subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation.
      This study is designed to evaluate the effect of LUM/IVA on manifestations of CF affected by
      exercise tolerance &amp; training.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02875366</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>